Cabazitaxel More Effective Than ADT: Prostate Cancer

Researchers recently discovered that cabazitaxel, compared with abiraterone or enzalutamide, is a potentially more effective drug to use in the fight against metastatic castration-resistant prostate cancer. Androgen-deprivation therapy (ADT), such as abiraterone or enzalutamide, hinders the body from producing testosterone, which fuels prostate cancer cells. However, resistance often occurs when this type of therapy is used. Cabazitaxel, an anti-microtubule chemotherapy drug, works by inhibiting...
Continue reading

Apalutamide for Metastatic Castration-Sensitive Prostate Cancer: Kim N. Chi, MD

On September 17, 2019, the FDA approved apalutamide (Erleada®, Janssen Biotech, Inc.) in combination with androgen deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (CSPC). The approval was based on TITAN (NCT02489318), a Phase III clinical trial led by Kim N. Chi, MD, Vice President of BC Cancer Agency in Vancouver and Professor of Medicine at the University of British Columbia. In this interview with i3 Health, Dr. Chi discusses the significance of the...
Continue reading

Prostate Cancer: Stereotactic Body Radiotherapy Safely Shortens Treatment

​ A phase 3 trial reports that stereotactic body radiotherapy (SBRT), which takes significantly less time than standard-of-care intensity-modulated fractionated radiotherapy (IMRT), is equally safe for patients with prostate cancer. The international, open-label PACE-B trial (NCT01584258) randomized 874 men with low- or intermediate-risk prostate adenocarcinoma in a 1:1 ratio to receive either SBRT (36.25 Gy) in five fractions over one to two weeks, or conventionally fractionated or moderately h...
Continue reading

Apalutamide Approved for Metastatic Castration-Sensitive Prostate Cancer

The FDA has approved apalutamide (Erleada®, Janssen Biotech, Inc.) in combination with androgen deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (CSPC). The approval was based on TITAN (NCT02489318), a randomized, double-blind, placebo-controlled, multicenter clinical trial that enrolled 1,052 patients with metastatic CSPC, including patients with both high- and low-volume disease. Prior treatment for localized disease and prior docetaxel therapy were a...
Continue reading

​Poultry Consumption Linked to Cancer Risk

In addition to the known cancer risks associated with consumption of red and processed meats, a new study warns of an increased cancer risk from poultry. "The latest meta-analysis from the World Cancer Research Fund/American Institute for Cancer Research concluded that red meat was a probable cause and processed meat a convincing cause of colorectal cancer," write the researchers in their presentation abstract in the Journal of Epidemiology and Community Health , led by first author Anika Knüppe...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.